The latest consensus on antiemetics

Jørn Herrstedt*

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftReviewForskningpeer review


Purpose of review The present review summarizes and discuss the most recent updated antiemetic consensus. Recent findings Two new neurokinin (NK) 1-receptor antagonists, netupitant and rolapitant, have been approved by the Food and Drug Administration and the European Medicines Agency and incorporated in the latest versions of the MASCC/ESMO, ASCO, and NCCN guidelines. Guidelines all recommend a combination of a serotonin (5-HT) 3-receptor antagonist, dexamethasone, and a NK 1-receptor antagonist in patients receiving highly emetogenic chemotherapy (HEC) with the addition of the multireceptor targeting agent, olanzapine, as an option in cisplatin or anthracycline-cyclophosphamide chemotherapy. A combination of a 5-HT 3-receptor antagonist, dexamethasone, and a NK 1-receptor antagonist is also recommended in patients receiving carboplatin-based chemotherapy, although based on a lower level of evidence. In spite of the development of new antiemetics, nausea has remained a significant adverse effect. Olanzapine is an effective antinausea agent, but sedation can be a problem. Therefore, the effect and tolerability of multitargeting, nonsedative agents like amisulpride, should be explored. Summary Guidelines recommend a combination of a 5-HT 3-receptor antagonist, dexamethasone, and an NK 1-receptor antagonist in HEC and carboplatin-based chemotherapy. The addition of olanzapine can be useful in cisplatin-based and anthracycline-cyclophosphamide-based chemotherapy in particular if the main problem is nausea.

Sider (fra-til)233-239
Antal sider7
TidsskriftCurrent Opinion in Oncology
Udgave nummer4
StatusUdgivet - 1 jul. 2018


Udforsk hvilke forskningsemner 'The latest consensus on antiemetics' indeholder.